Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner-Lambert retains Zantac 75 North America rights after Glaxo venture dissolves.

This article was originally published in The Tan Sheet

Executive Summary

WARNER-LAMBERT ZANTAC 75 RIGHTS IN NORTH AMERICA RETAINED following dissolution of the firm's joint venture with Glaxo Wellcome for over- the-counter drugs. Under the new arrangement, announced Aug. 3, Warner-Lambert will pay Glaxo Wellcome for the cost of supplying the H2 antagonist ranitidine; there is no royalty component to the agreement. Zantac 75 sales in the U.S. through the half totaled $84 mil. Worldwide sales in 1997 were $161 mil. Zantac 75 is third in the acid blocker market in terms of dollar sales and had a 10.5% market share in 1997 in food, drug and mass merchandise retail channels, according to Information Resources, Inc. (Chicago).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel